Vencio Sérgio, Vianna André Gustavo Daher, da Silva Mariana Arruda Camara Ferreira, Precoma Dalton Bertolim
UFG - Federal University of Goiás, Goiânia, GO, Brazil.
ICF, Pharmaceutical Institute of Science, Av. Rio Verde, S/N - Cidade Vera Cruz, Aparecida de Goiânia, GO, 74935-530, Brazil.
Diabetol Metab Syndr. 2022 Jan 10;14(1):5. doi: 10.1186/s13098-021-00775-9.
Type 2 diabetes (T2D) is a known risk factor for cardiovascular disease (CVD), and CVD is a major cause of mortality in patients with T2D. The CAPTURE study investigated the contemporary (2019) prevalence of established CVD in adults with T2D around the world. We report the findings from Brazil.
The multinational, non-interventional, cross-sectional CAPTURE study was conducted across 13 countries from five continents. The current manuscript explores data for the CAPTURE study sample in Brazil. Standardized demographic and clinical data were collected from adults with T2D aged ≥ 18 years attending a single routine healthcare visit in primary or specialized care between December 2018 and September 2019. Data were analyzed descriptively.
Data from 912 adults with T2D were collected in the CAPTURE study in Brazil, with 822 patients from primary care and 90 patients from specialized care. Median (interquartile range [IQR]) patient characteristics were as follows: age 64 years (57; 71), diabetes duration 11 years (6; 19), glycated hemoglobin 7.7% (6.7; 9.1), and body mass index 29.5 kg/m (26.4; 33.5); 59% were female. The CVD prevalence and atherosclerotic CVD prevalence in the Brazil sample were 43.9% (95% confidence interval [CI] 40.9; 46.8) and 37.6% (95% CI 34.7; 40.5), respectively. The majority of patients with CVD had atherosclerotic CVD (85.8%). For the specific CVD subtypes, coronary heart disease prevalence was 27.9% (95% CI 25.2; 30.5), heart failure was 12.4% (95% CI 10.4; 14.4), cerebrovascular disease was 8.7% (95% CI 6.8; 10.5), and carotid artery disease was 3.4% (95% CI 2.3; 4.5). Glucagon-like peptide-1 receptor agonists and/or sodium-glucose co-transporter-2 inhibitors with proven cardiovascular benefit were prescribed to 15.5% of patients with CVD, compared with 18.4% of patients without CVD.
CAPTURE was the first multinational, standardized study to provide contemporary data on CVD prevalence in adults with T2D in Brazil, and it demonstrated that almost one in two adults with T2D had established CVD. Except for carotid artery disease, the prevalence of all CVD subtypes in adults with T2D in Brazil appeared higher than the global CAPTURE prevalence. Trial registration NCT03786406, NCT03811288.
2型糖尿病（T2D）是已知的心血管疾病（CVD）危险因素，而CVD是T2D患者死亡的主要原因。CAPTURE研究调查了2019年全球成年T2D患者中已确诊CVD的流行情况。我们报告巴西的研究结果。
这项跨国、非干预性横断面CAPTURE研究在来自五大洲的13个国家开展。本手稿探讨了巴西CAPTURE研究样本的数据。从2018年12月至2019年9月期间在基层或专科护理机构接受单次常规医疗就诊的年龄≥18岁的成年T2D患者中收集标准化的人口统计学和临床数据。对数据进行描述性分析。
在巴西的CAPTURE研究中收集了912例成年T2D患者的数据，其中822例来自基层医疗，90例来自专科医疗。患者的中位（四分位间距[IQR]）特征如下：年龄64岁（57；71），糖尿病病程11年（6；19），糖化血红蛋白7.7%（6.7；9.1），体重指数29.5kg/m²（26.4；33.5）；59%为女性。巴西样本中CVD患病率和动脉粥样硬化性CVD患病率分别为43.9%（95%置信区间[CI]40.9；46.8）和37.6%（95%CI 34.7；40.5）。大多数CVD患者患有动脉粥样硬化性CVD（85.8%）。对于特定的CVD亚型，冠心病患病率为27.9%（95%CI 25.2；30.5），心力衰竭为12.4%（95%CI 10.4；14.4），脑血管疾病为8.7%（95%CI 6.8；10.5），颈动脉疾病为3.4%（95%CI 2.3；4.5）。有心血管获益证据的胰高血糖素样肽-1受体激动剂和/或钠-葡萄糖协同转运蛋白2抑制剂被处方给15.5%的CVD患者，而未患CVD的患者这一比例为18.4%。
CAPTURE是第一项提供巴西成年T2D患者CVD流行情况当代数据的跨国标准化研究，它表明几乎每两名成年T2D患者中就有一人患有已确诊的CVD。除颈动脉疾病外，巴西成年T2D患者中所有CVD亚型的患病率似乎高于全球CAPTURE研究中的患病率。试验注册号：NCT03786406，NCT03811288。
